Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Eliquis in a Phase II trial. The randomised open-label pivotal trial (NCT06689436) enrolled 60 healthy volunteers. Of those, 48 went on to complete the trial over four arms, two who were made to ...